Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO2 | P16083 | 1/20 | 0.48 |
| ▸ | EGFR | P00533 | 3/20 | 0.43 |
| ▸ | KDM4A | O75164 | 1/20 | 0.43 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.42 |
| ▸ | MIF | P14174 | 1/20 | 0.42 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32665544 | 0.88 | CA12 (0.49) | NQO2EGFRKDM4AKCNA5MIF | |
| SCHEMBL4763233 | 0.85 | GRM2 (0.48) | KDM4AKCNA5GRM2KDM4ELMNA | |
| SCHEMBL700928 | 0.85 | IDO1 (0.50) | KDM4AKCNA5GRM2KDM4EIDO1 | |
| Hydrochloric Acid SCHEMBL709884 | 0.84 | IDO1 (0.49) | KDM4AKCNA5GRM2KDM4EIDO1 | |
| SCHEMBL4894133 | 0.82 | NQO2 (0.49) | NQO2EGFRKDM4AKCNA5MIF | |
| SCHEMBL2940084 | 0.81 | NQO2 (0.48) | NQO2EGFRKDM4AKDM4EGAA | |
| SCHEMBL11346674 | 0.80 | NQO2 (0.47) | NQO2EGFRKDM4AKCNA5GAA | |
| SCHEMBL24885830 | 0.79 | NQO2 (0.49) | NQO2EGFRKDM4AKCNA5MIF | |
| SCHEMBL8417963 | 0.77 | HPN (0.49) | EGFRKDM4AGRM2GAAHDAC1 | |
| SCHEMBL4898444 | 0.76 | NQO2 (0.47) | NQO2EGFRKDM4AKCNA5MIF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260021192-A1 | PROTEINS HAVING A COVALENT WARHEAD | TOPAZ THERAPEUTICS INC (US) | 2026-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260021192-A1 | PROTEINS HAVING A COVALENT WARHEAD | RIOX2, ORC3, DCLRE1A | NQO2 3121/4885EGFR 1861/4885KDM4A 4180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.